NIH R01 · 2025
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease
PROJECT SUMMARY/ABSTRACT There is a critical need for effective pharmacotherapy for the management of non-alcoholic fatty liver disease (NAFLD). The proposed research is to conduct early-stage preclinical validation of new therapeutic leads that target thioesterase superfamily member 1 (Them1; synonym Acyl-CoA thioesterase 11), a key enzyme of fatty acid metabolism that becomes maladaptive in NAFLD. The long-term goal is to develop inhibitors of Them1 as a therapeutic modality in the management of human NAFLD. The objective of this research is to optimize the drug-like properties of small molecule inhibitors in order to create lead compounds, and to demonstrate their safety, efficacy and…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.